Plasmodium Vivax Malaria Clinical Trial
Official title:
A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil
The current treatment recommendations for P. vivax in pregnant and non-pregnant individuals are to use chloroquine; in non-pregnant patients this is followed by primaquine to prevent relapse. As primaquine can not be used in pregnant women, these women remain at risk of relapse. As there is increasing concern about chloroquine resistant P. vivax in this region, there is a need to identify alternative treatment options. The artemisinin combination therapies are recommended for use against P. falciparum infections in pregnant women after the 1st trimester; additional data are needed to support the use of these drugs against P. vivax.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04416945 -
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
|
N/A | |
Recruiting |
NCT05052502 -
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
|
N/A | |
Completed |
NCT00295581 -
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
|
Phase 1 | |
Recruiting |
NCT05788094 -
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
|
Phase 4 | |
Completed |
NCT02001428 -
Malaria in Early Life Study
|
N/A | |
Completed |
NCT02123290 -
DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
|
Phase 2 | |
Completed |
NCT01887821 -
Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
|
Phase 4 | |
Terminated |
NCT00138489 -
Papua New Guinean Duffy Negativity And Vivax Malar
|
||
Not yet recruiting |
NCT04704999 -
Southeast Asia Dose Optimization of Tafenoquine
|
Phase 4 | |
Completed |
NCT00935623 -
Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans
|
Phase 1 |